The mycotoxin ochratoxin A (OTA) is a potent renal carcinogen in rodents and induces renal fibrosis in pigs. Furthermore, OTA has been associated with the development of renal tumors and nephropathies in humans. Large species-and sex-differences are observed in sensitivity toward OTA-mediated toxicity and carcinogenicity, yet neither the mechanism(s) resulting in OTA toxicity nor the reasons for the observed species-and sex-specificities are known. This paper investigated variations in OTA handling viz binding to renal proteins which could possibly explain the observed differences in OTA susceptibility in vivo and in vitro. The results obtained via a modification of a standard receptor-binding assay demonstrated the presence of at least one homogeneous binding component in renal cortical homogenates from pig, mouse, rat and humans. This component was shown to bind OTA in a specific and saturable manner. A range of compounds selected for their affinity for steroid receptors and/or for various known organic anion transporters were employed in a competition assay to answer the question whether this homogenous OTA binding component represents a steroid-like receptor component or one of the known organic anion transporters of the kidney. Although many of the compounds were able to compete with OTA for protein-binding, the competition patterns displayed a distinct species specificity and did not correspond to the competition patterns associated with presently known organic anion transporters of the kidney in the mouse, rat or human. The data thus suggests the presence of a new organic anion transporter or more likely, a cytosolic binding component of unknown function with high affinity and capacity for OTA binding in humans, rats, mice and possibly pigs. 
Introduction
The mycotoxin ochratoxin A (OTA), a secondary metabolite of ubiquitous Aspergillus and Penicillium species, is a known contaminant of human foodstuffs (SPEIJERS and VAN EGMOND 1993; STUDER-ROHR et al. 1995; WOLFF et al. 2000) . In a number of in vivo models OTA has been observed to induce renal tumors (mice and rats) and nephropathies (pigs) (ELLING 1983) . Tumor-incidence was markedly species-and sex-specific with males being at least 10-times more susceptible than females DIETRICH and RASONYI 1995; RASONYI et al. 1999; BENDELE et al. 1985) . Moreover, OTA has also been associated with the high incidences of human urinary tract tumors and nephropathies in endemic areas of the Balkans (TATU et al. 1998) .
Similarly, stark species-and sex-specific variations in OTA-mediated toxicity have also been observed in renal epithelial cells in vitro (O'BRIEN et al. 2001; . Whether these species-and sex-specific differences are governed by specific renal handling of OTA is the subject of the present investigation. Indeed, the comparison of serum/plasma half-lives of OTA in a number of species -35.5 days in humans (STUDER-ROHR et al. 2000) , 21-35 days in monkeys (HAGELBERG et al. 1989) , 40 hours in mice (FUKUI et al. 1987, HAGELBERG et al. The study presented here, therefore investigated interspecies and inter-sex variations in the binding capacities and/or affinities of OTA to renal cortical proteins by using a classical competitive protein-binding assay with tritiated OTA and protein homogenates of renal cortical tissue of both sexes, from relevant model species (rat, mouse, pig) and from humans. The compounds chosen as competitors for the detection of a potential renal OTA binding protein included ochratoxin B (OTB), (a natural analog of OTA, which differs from OTA only by the substitution of a hydrogen for the chlorine on the isocoumarin moiety), fumonisin B 1 (FB 1 , a secondary metabolite of Fusarium moniliformes), cephaloridine, nalidixic acid, furosemide, ethacrynic acid, indomethacin, valproate, sulfobromophthalein (BSP), dehydroiso-androsterone-3-sulfate (DHEAS), digoxin, several bile acids, p-aminohippurate (PAH), caprylic acid, probenecid, piroxicam, α-ketoglutarate, steroids, coumarin and phenylalanine. While OTB, coumarin, phenylalanine and the steroids were specifically chosen for their immediate structural analogies to OTA, OTB was also of interest due to its significantly lower toxicity in vivo (DOSTER et al. 1972; PECKHAM et al. 1971 ). All compounds other than FB 1 were chosen either because they have been shown to be substrates of the renal organic anion transporters suggested to be responsible for OTA transport (table 1) in the respective animals (ENDOU, 1998; ROCH-RAMEL, 1998; SAUVANT et al. 1998) or because of their known potency to inhibit OTA uptake into proximal tubular cells GROVES et al. 1999; WELBORN et al. 1998) .
Thus, the focus of this study was to examine OTA binding to renal proteins and to investigate sex-and species-specific differences in binding patterns, which could explain the in vivo and in vitro observed toxicity differences. The data obtained should provide a basis for future research as well as for the comparison with previously published data.
Materials and methods

Materials:
Highly purified ochratoxin A and B (> 98% purity, benzene free) were kindly provided by Dr. M. E. Stack, U.S. FDA, Washington, D.C. Unless otherwise stated, all other chemicals were purchased from Sigma, Taufkirchen, Germany. 3 H]-OTA/OTA (1:1) at final concentrations ranging between 50-800 nM in the presence or absence of 1,000-fold excess OTA at room temperature for 1 hour in order to determine non-specific binding (NB) and total binding (TB), respectively. Unbound [ 3 H]-OTA was removed from the solution by the addition of 300 µl dextran (0.375%)-coated charcoal (3.75%) suspension in 0.01 M Tris-HCl, pH 7.4, to each sample tube. The tubes were vigorously mixed and then centrifuged at 12,000 rpm for 10 seconds at room temperature using an Eppendorf microfuge. A 300 µl aliquot of the resulting supernatant was mixed with 3 ml scintillation fluid (Ready Safe, Beckman, Fullerton, U.S.A.) and quantified by liquid scintillation spectrometry using a LS 6500 scintillation counter (Beckman, Fullerton, U.S.A.). Specific binding (SB) was calculated as the difference between TB and NB. K D and b max were calculated by Scatchard analysis and non-linear regression analysis using GraphPad Prism software.
For competition binding studies approximately 0.5 mg cortex protein in a final volume of 280 µl were incubated with [
3 H]-OTA/OTA (1:1) at a final concentration of 100 nM in the presence or absence of 1,000-fold excess OTA.
[ 3 H]-ochratoxin A with a specific activity of 6.66 Bq/mmol was purchased from Moravek Biochemicals, U.S.A., and was diluted with absolute ethanol. Stock solutions and dilutions of potential binding competitors were prepared with the appropriate vehicle as listed in table 2.
Animals and tissues:
Female and male Fischer rats (CDF ® (F344)/Crl BR) (150-200g) and C57Bl/6J×C3H, F1-mice were purchased from Charles River, Germany and Harlan, Germany, respectively, and maintained by veterinarians and specifically skilled animal personnel in the animal research facility (TFA) of the University of Konstanz.
Whole kidneys from freshly-killed improved German hybrid pigs of both sexes were obtained from a local slaughter-house.
Human tissue samples: Human renal biopsy material (male and female patients) was obtained from a local hospital (Klinikum Konstanz) in collaboration with the Department of Urology, Prof. Dr. Hochberg and Prof. Dr. Thiel, subsequent to patient information and receipt of the signed patient's consent form. Tissue samples as well as patient data were handled in accordance to the stipulations put forth by the ethics committee of the University of Konstanz and in fulfillment of German law and the Declaration of Helsinki (1964) pertaining to personal data protection and handling of human biopsy material.
Preparation of protein samples:
Human and animal renal cortex samples were placed in ice-cold homogenization buffer (10 mM Tris, 1.5 mM EDTA, 20 mM sodium molybdate, 10% (v/v) glycerol, 0.1 % (v/v) monothioglycerol, 0.4 mM PMSF, pH 7.4) and minced with a scissors. Samples were homogenized using 10 strokes of a motordriven teflon pestle in a glass tube. The crude homogenates were then centrifuged at 4 °C for 20 min at 10,000×g. Supernatants were collected and protein content was determined using the standard Bradford procedure. All samples were diluted with homogenization buffer to 5 mg protein/ml, aliquoted and stored at -80 °C until use. The competitive binding capacity of each test substance was determined using the same procedure as described for non-specific binding above except that increasing concentrations of potential competitors were added instead of excess OTA. All assays were carried out at least three times in duplicate and included both OTA and OTB as positive controls. The resulting data were plotted as percentage of control (specific-binding in the absence of competitor) versus the log of competitor concentrations.
Statistical analysis:
Results from protein binding experiments were expressed as percentage vehicle control and analyzed with a one-tailed Dunnett's test. The effective concentrations causing 20% effect (EC 20 ) and 50% effect (EC 50 ) of each substance were calculated from concentration-response curves fitted by GraphPad Prism version 3.00 for Windows and Excel software (Microsoft Excel 2000) . The data are presented as arithmetic means with their corresponding 95% confidence intervals, or, in the case of description of protein binding characteristics with their standard deviations (SD) (table 3).
Results
Characterization of protein binding. fig.1A and B) linear regression analysis, respectively (table 3) . Although Scatchard analysis is outdated for numerous mathematical reasons (distortion of the experimental error, violation of the assumption of linear regression) and therefore not ideal for use in this type of data analysis, it was used in this study in addition to non-linear regression analysis to allow for better comparison with the data in previously published studies. The data in table 3 suggested the presence of a homogeneous binding component having the characteristic of binding OTA in a specific and saturable manner. However, the K D and b max values displayed large SDs, presumably due to different levels of protein expression of the respective animals and human biopsy samples. In contrast, comparison of the values for specific binding, yielded a more reliable picture and obvious capacity ranking: human > rat > pig ≥ mouse, with human tissues having an approximately 20-fold higher binding capacity for OTA than mouse renal cortex homogenates. Concentration-response curves were generated for all species using OTA and OTB. As the curves for all species were similar, only figure 3, which represents the behavior of human proteins, is shown. The data from other species are summarized in table 4. An OTA competition sensitivity ranking was deduced from the EC 50 data As expected, a similar sensitivity ranking to OTA (see above) could be deduced for OTB using the EC 50 data [µM ( shown), with males having an approximately 3-fold higher binding affinity for OTB than females. However, higher concentrations were necessary to achieve the same competition levels. For human proteins, this represented approximately a factor of 5, approximately a factor of 10 for rat proteins and more than a factor of 15 for both mouse and porcine proteins.
BSP, a ligand for organic anion carriers expressed in the liver and kidney of the rat (KUSUHARA et al. 1999; TSUDA et al. 1999 ), competed for [ 3 H]-OTA binding with a similar potency as OTA (nM -low µM range) in rat and mouse. However, only weak competition was observed (high µM range) in the pig and human samples.
Indomethacin, a known inhibitor of the renal organic anion transporter of the rat (OAT1) (SEKINE et al. 1997) , mouse (mOAT1) (KUZE et al. 1999 ) and human (hOAT1) (HOSOYAMADA et al. 1999) , was a potent competitor of OTA (first effects in nM range) in the rat and human samples but not in the mouse or the pig. Kidney samples from female humans appeared nearly 10-fold more sensitive to OTA binding competition by indomethacin than the corresponding male samples (table 4), suggesting either differences in binding-protein expression levels or a completely different binding-protein expression pattern.
Furosemide, also an inhibitor of rat and human renal organic anion transporters (SEKINE, et al. 1997; KUSUHARA et al. 1999; SAITO et al. 1996; MASUDA et al. 1999 , HOSOYAMADA et al. 1999 ), competed with [ 3 H]-OTA only at higher concentrations in the rat and human and only very weakly in the mouse. However, furosemide was a potent competitor of [ 3 H]-OTA binding in pigs, with females displaying a flatter slope of the concentration-response curve than males. Indeed, females displayed first significant competition of OTA binding at a 60-fold lower furosemide concentration than the one necessary to obtain the same effect in males.
Piroxicam, a known inhibitor of rat organic anion transporters (TSUDA et al. 1999 , KUSUHARA et al. 1999 , competed with human and rat [ 3 H]-OTA protein binding at relatively high concentrations (upper µM range). Female mouse and female pig samples showed slight inhibition at millimolar concentrations, while male mouse and male pigs were completely refractive.
Only very weak competition was observed in rat and human samples with nalidixic acid, ethacrynic acid, probenecid and caprylic acid at relatively high concentrations (µM to mM range). Similarly nalidixic acid provided a weak competion in female but not in male mouse samples. Millimolar concentrations of nalidixic acid, ethacrynic acid, probenecid and caprylic acid were necessary to produce binding inhibition in male and female pig samples, while ethacrynic acid, probenecid and caprylic acid had no competitive acitvity in either female or male mouse samples.
With the exception of DHEAS, none of the steroidal compounds had any competitive activity for OTA protein binding. DHEAS, at µM concentrations, inhibited [ 3 H]-OTA protein binding however only in mouse and rat samples .
Discussion
The saturation binding curves and corresponding Scatchard analyses obtained with [ 3 H]-OTA and the kidney homogenates suggested the presence of a homogeneous binding component in all species tested. This (these) homogeneous binding component(s) characteristically bound OTA in a specific and saturable manner, while having a low affinity but high capacity for OTA binding. The latter was deduced from the fact that relatively high concentrations of OTA were necessary to 156 Exp Toxic Pathol 54 (2002) 2
